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a  b  s  t  r  a  c  t
Live-attenuated  rubella  vaccine  strain  RA27/3  has  been  demonstrated  to be  safe  and  immunogenic  in
millions  of children.  The  vaccine  strain  was  used  to insert  SIV gag  sequences  and  the  resulting  rubella
vectors  were  tested  in  rhesus  macaques  alone  and  together  with  SIV  gag  DNA  in  different  vaccine  prime-
boost  combinations.  We  previously  reported  that  such  rubella  vectors  induce  robust  and  durable  SIV-
speciﬁc  humoral  immune  responses  in  macaques.  Here,  we  report  that  recombinant  rubella  vectors  elicit
robust  de  novo SIV-speciﬁc  cellular  immune  responses  detectable  for >10  months  even  after  a  single
vaccination.  The  antigen-speciﬁc  responses  induced  by  the  rubella  vector  include  central  and  effector
memory  CD4+ and  CD8+ T cells  with  cytotoxic  potential.  Rubella  vectors  can  be  administered  repeatedly
even  after  vaccination  with  the  rubella  vaccine  strain  RA27/3.  Vaccine  regimens  including  rubella  vector
and SIV  gag DNA  in  different  prime-boost  combinations  resulted  in  robust  long-lasting  cellular  responses
with signiﬁcant  increase  of cellular  responses  upon  boost.  Rubella  vectors  provide  a potent  platform  for
inducing  HIV-speciﬁc  immunity  that can be  combined  with  DNA  in a prime-boost  regimen  to  elicit  durable
cellular  immunity.ytotoxic T cells
NA vaccine
M9  tetramer response
FN- response
IV vaccine
NA prime rubella boost
ubella prime boost
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Several viral vectors are being pursued as potential vehicles
o express HIV antigens including CMV, measles, mumps, rubella,
denovirus, vaccinia, yellow fever, VSV and varicella [1–26]. The
ive-attenuated rubella vaccine strain RA27/3 has a proven track
ecord for safety and immunogenicity efﬁcacy [27–29] with a single
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201, USA. Tel.: +1 301 846 5159; fax: +1 301 846 7146.
E-mail addresses: ira.berkower@fda.hhs.gov (I. Berkower),
arbara.felber@nih.gov (B.K. Felber).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.067
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-Ndose shown to induce humoral immunity and life-long protection
against rubella infection. Rubella vaccine can also boost previously
immunized persons, even in the presence of pre-existing rubella
immunity [30]. The generation of rubella vectors carrying HIV
genes has the potential to elicit durable immunity. The challeng-
ing task is the generation of viable recombinant rubella carrying
immunogens of the required length. We  previously demonstrated
that rubella vaccine strain RA27/3 [31] can accommodate insertions
up to ∼300 amino acids of SIV Gag at the structural insertion site
located between the envelope E2 and E1 [18,21]. Gene expression
at this site is controlled by the strong subgenomic promoter, which
assures efﬁcient expression of the insert.
Using recombinant rubella vectors in macaques, we  reported the
induction of robust SIV/HIV-speciﬁc humoral responses [21], which
could be boosted upon re-exposure to the vector, indicating the
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Vaccination protocols. The cartoon is an adaptation from Virnik et al. [19] and details the vaccination timeline used for this Indian rhesus macaque study. Animals
CL6A  and CL6J had received RA27/3 rubella vaccine strains and sham DNA. Macaques CL67, CL49, CL6V had received rubella types 1 and 2 which were “no takes” and did
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mot  induce antibodies to rubella and also did not induce Gag-speciﬁc T cell immun
ype  3*, referred to as rubella vector herein, expressing SIV Gag. The animals were an
aplotype were also analyzed for Gag CM9  tetramer responses.
evelopment of memory B cells. Different prime-boost combina-
ions including recombinant rubella vectors and DNA elicited even
igher antibody responses with extended longevity (>9 months),
ndicating that the rubella-induced responses could be further aug-
ented.
DNA as vaccine platform has several advantages related to
ts simplicity, scalability, and possibility of repeated applications
ue to lack of immunity against the vector (reviewed in [32]).
IV/SIV DNA vaccines administered by the intramuscular route
IM) followed by in vivo electroporation (EP) were shown to induce
igh cellular and humoral immune responses that persisted for
5 years after the last vaccination [33–35]. The potency of these
ellular immune responses was demonstrated by their ability to
reatly reduce viremia in macaques infected with pathogenic SIV
r SHIV, in both preventive and therapeutic vaccine studies [32].
umoral responses could be signiﬁcantly augmented by combin-
ng DNA vaccine with different boosts (protein, recombinant viral
ectors) [32].
In this report, we examined the Gag-speciﬁc cellular immune
esponses from macaques vaccinated with rubella vectors or
ith DNA and rubella vectors in different prime-boost combina-
ions. We  focused on Gag as antigen, because Gag-speciﬁc T cell
esponses were reported to correlate with control of viremia in
nfected individuals [36–39] and such responses are expected to
educe viremia in both preventive and therapeutic vaccination
rotocols.
. Methods
.1. Cellular immune response analysis in vaccinated macaques
Macaques were sequentially vaccinated via the IM route [19]
ith rubella vectors expressing four T cell epitopes (GY9, TE15, CM9
nd ME11; vector type 3) or p27gag and part of p2gag (amino acids
35–391 of Gag; vector type 3*) of SIVmac239 Gag [19] and SIV gag
NAs [40].
Gag-speciﬁc cellular immune responses were measured at the
ay of vaccination and indicated time points thereafter using a Gag
eptide pool [33] and Gag181–189 CM9  tetramer [41] in MamuA*01+
acaques as detailed in Supplementary methods.e animals received sequential vaccinations with DNA and rubella vector type 3 or
d for Gag-speciﬁc IFN- T cell responses, and macaques positive for the MamuA*01
3. Results
3.1. Sequential vaccination regimens using recombinant rubella
vectors and DNA
We  tested the ability of recombinant rubella vectors to induce
Gag-speciﬁc cellular immune responses in macaques. Fig. 1 shows
the vaccination regimens, which included rubella vectors and DNA
expressing SIV gag in different prime-boost regimens. Rubella vec-
tor type 3 and type 3* differ by the size of the gag insert, comprising
4 epitopes located in the p19gag and p27gag regions (type 3) or
the complete p27gag and p2gag (type 3*), and both elicited anti-
bodies against Rubella and SIV Gag in vaccinated macaques [19].
Some of the macaques were recycled from a previous study where
they received the rubella vaccine strain RA27/3 (rubella vaccine)
or rubella vectors types 1 and 2 which did not replicate in vivo or
show a vaccine “take” and did not develop humoral [19] or cellular
immunity to Gag (not shown).
This report focuses on the induction and characterization of cel-
lular immune responses addressing the following questions: (i)
Can rubella vector vaccination induce de novo Gag-speciﬁc cellu-
lar immune responses (5 animals: CL6A, CL6J, DCVV, CL67, CL49)?
(ii) Can DNA vaccination boost pre-existing rubella vector induced
responses (3 animals: CL67, CL49, DCVV)? (iii) Can rubella vector
vaccination boost pre-existing DNA induced responses (7 animals:
CL67, CL49, DCVV, CL6V, J6L, V584, V200)? (iv) Can a 2nd rubella
vector vaccination boost responses after rubella vector priming (all
9 animals: CL6A, CL6J, CL67, CL49, DCVV, CL6V, J6L, V584, V200)?
3.2. Vaccination with rubella vectors induces Gag-speciﬁc T cell
responses in macaques
Two macaques (CL6A, CL6J), previously vaccinated with the
live-attenuated rubella vaccine strain RA27/3, were immunized
one year later, when the anti-rubella antibody titer had slightly
declined, with the rubella vector expressing SIV Gag. A single vacci-
nation with rubella vector was  able to induce Gag-speciﬁc cellular
responses in both macaques, reaching up to ∼0.2% IFN-+ T cells
(Fig. 2A). In CL6A, the responses were mediated by similar levels of
CD4+ and CD8+ T cells, while CL6J showed a primarily CD4+ T cell
M.  Rosati et al. / Vaccine 33
Fig. 2. Recombinant rubella vector vaccination induces de novo Gag-speciﬁc responses
in macaques. (A) CD4+ and CD8+ Gag-speciﬁc IFN- T cell responses measured
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a weeks after vaccination with the rubella vector in ﬁve animals (CL6A, CL6J,
CVV, CL49, CL67). (B) Dot plots show CM9  Gag tetramer responses in MamuA*01+
acaques (CL6A and CL49) at the day of vaccination and 2 weeks later.
esponse. The MamuA*01+ CL6A also showed a robust CM9-speciﬁc
esponse, reaching ∼2.9% of CD8+ T cells (Fig. 2B, upper panels).
Three other macaques (DCVV, CL49, and CL67) that developed
nti-Rubella and anti-Gag antibody responses after a single immu-
ization with the rubella vector [19], were also examined for
ag-speciﬁc IFN-+ cellular immune responses (Fig. 2A). DCVV
eveloped Gag-speciﬁc T cells (0.13%); CL49 did not develop a Gag-
peciﬁc T cell response upon peptide stimulation, but showed low
evels (0.03%) of Gag CM9+-speciﬁc T cells, while CL67 failed to
how Gag-speciﬁc T cell immunity. The difference in responsive-
ess could reﬂect known animal-to-animal variation of outbred
acaques as we observed in prior studies [33,34,40]. Together,
hese data show that a single vaccination with rubella vector
nduced Gag-speciﬁc T cell responses in 4 of the 5 animals tested
80% response rate). A single vaccination with rubella vector
nduced Gag-speciﬁc T cell responses comparable to those obtained
pon a single gag DNA vaccination (1 mg  dose) using the efﬁcient
P delivery method with a mean response of 0.025% IFN-+ T cells
unpublished). These responses were also similar to those obtained
pon IM delivery of the Vaxfectin® adjuvanted DNA (1 mg  dose)
hich, although low, contributed to control of viremia [42].
.3. gag DNA vaccination in rubella vector primed macaques
We  examined the effect of gag DNA boost in three animals (CL49,
L67, DVCC) previously vaccinated with rubella vector (Fig. 3A ).
pon rubella vector vaccination, all animals were positive for anti-
ubella and anti-Gag antibody responses [19], and macaques DCVV
nd CL49 were also positive for Gag cellular responses (Fig. 3A, (2015) 2167–2174 2169
week 20 of study; data from Fig. 2). Upon a single DNA vaccination
(week 25 of study), all three animals showed an increase of the Gag-
speciﬁc T cells ranging from 0.02 to 0.5% of IFN-+ T cells (upper
panels, week 27). Analysis of the MamuA*01+ CL49 also demon-
strated an increase of the CM9  response to 0.7% of CD8+ T cells
(lower panel). Pre-existing immunity to rubella did not prevent
successful vaccination with gag DNA.
3.4. Rubella vector boost of DNA-primed macaques
We tested the ability of rubella vector to boost pre-existing
immunity induced by gag DNA vaccination in four macaques
(Fig. 3B). The gag DNA vaccine induced robust responses ranging
from 0.25 to 0.5% of IFN-+ T cells (J6L, V584, V200, upper panels;
note CL6V, could only be evaluated for the tetramer responses),
similar to our previous results with IM/EP vaccinated macaques
[33,34,40]. The MamuA*01+ J6L, V584 and CL6V also developed
robust tetramer responses reaching ∼2% to 5% of CD8+ T cells (lower
panels). The DNA-primed animals received a rubella vector vacci-
nation (week 25 for J6L, V584, V200; week 57 for CL6V), resulting
in increased Gag-speciﬁc responses (∼2-fold; reaching ∼0.5% of T
cells) as well as an increase of the CM9  responses (3- to 5-fold;
reaching ∼4–12% CD8+ T cells). In all animals, the Gag-speciﬁc
responses were higher after the rubella vector boost compared to
the peak responses obtained upon DNA vaccination, indicating a
beneﬁt of DNA vaccine prime and rubella vector boost regimen.
3.5. Boosting of pre-existing rubella vector induced immunity by
2nd rubella vector vaccination
To examine whether the Gag-speciﬁc cellular responses in
rubella vector-primed macaques could be boosted by a 2nd vec-
tor vaccination, we tested animals primed with rubella vector only
(Fig. 3C) or with DNA/rubella prime boost regimens (Fig. 3A and B).
Two  macaques (CL6A, CL6J) primed with rubella vector had
detectable Gag-speciﬁc cellular immune responses 11 months
later, when they received a 2nd rubella vector vaccine (Fig. 3C).
This boost led to an increase of the T cell responses in CL6A of
both Gag-speciﬁc IFN-+ T cells (∼0.2%) and the CM9+ CD8+ T cell
responses (3%), and had a lesser effect in CL6J. The DNA primed-
rubella vector boosted animals (J6L, V584, V200, CL6V; Fig. 3B) were
immunized with a 2nd dose of recombinant rubella vector after a
rest period of 8 to 11 months [week 57 (J6L, V584, V200) or week
100 (CL6V) of study]. In all macaques, the Gag-speciﬁc responses
increased reaching 0.1–0.2% of IFN-+ T cells (upper panels) and
1.5–7% of CM9+ CD8+ T cells (lower panels). Similarly, rubella vec-
tor and DNA-primed macaques (CL49, CL67, DCVV; Fig. 3A) received
a 2nd dose of recombinant rubella vector after a 17.5 months rest
period (week 100 of study). Two (CL49, DCVV) of three animals
showed an increase of the Gag-speciﬁc IFN-+ T cells (0.2 to 0.4%,
week 102 of the study, upper panels), and CL49 showed an increase,
reaching ∼4%, of CM9+ CD8+ T cells (lower panel, week 102 of the
study).
Together, we  found that repeated vaccination with rubella vec-
tor is feasible and that a 2nd dose of rubella vector resulted in
a statistically signiﬁcant increase of Gag immune response (N = 8,
Fig. 3D), including both the IFN- T cell (left panel) and tetramer
responses (right panel). Our data further showed that DNA-primed
macaques beneﬁtted from a rubella vector boost given after var-
ious rest times (7 weeks and 6.5 months Fig. 3B; 17.5 months,
Fig. 3A). Rubella vector vaccination signiﬁcantly boosted the Gag
cellular immunity in DNA-primed macaques (Fig. 3E) for both the
IFN- T cell (left panel) and the tetramer responses (right panel).
Thus, rubella vector boosts could be administered a long time after
the DNA priming, leading to a rapid and signiﬁcant increase of
Gag—speciﬁc cellular immunity. Together, these data demonstrate
2170 M. Rosati et al. / Vaccine 33 (2015) 2167–2174
Fig. 3. Responses after different prime boost regimens with rubella vector and gag DNA. (A) DNA vaccination of rubella vector primed macaques, and a 2nd rubella vector
boost.  The Gag-speciﬁc IFN-+ T cell responses (upper panels) of macaques CL67, CL49, and DCVV and the Gag CM9  tetramer-speciﬁc CD8+ T cells of the MamuA*01+
CL49 (lower panel) were measured at the indicated time points. The data from weeks 18 and 20 are from Fig. 2A. (B) Rubella vector boosts of DNA-primed macaques. The
Gag-speciﬁc IFN-+ T cells of J6L, V584 and V200 (top panels), and the CM9  tetramer-speciﬁc CD8+ T cells of the MamuA*01+ J6L, V584 and CL6V (lower panels) were
measured at the indicated time points. CL6V could not be analyzed for Gag-speciﬁc IFN-+ T cell responses due to high background levels in the unstimulated PBMC at all
time  points. (C) Gag-speciﬁc responses of two  macaques (CL6A, CL6J) after vaccination with rubella vector only. The Gag-speciﬁc IFN-+ T cell responses (black bars) are
shown  for both macaques, and the CM9  tetramer responses (gray bars) are shown for the MamuA*01+ CL6A. Data after the 1st rubella vector vaccination are from Fig. 2. (D)
Changes  in cellular immunity upon a 2nd rubella vector vaccination. Gag-speciﬁc IFN-+ T cells (left panel) and CM9  tetramer-speciﬁc CD8+ T cells (right panel) are shown
at  day of vaccination and 2 weeks later. P values were obtained using paired t test. Left panel includes data from 8 macaques shown in (A) (CL49, CL67, DCVV; weeks 100–102),
ine 33 (2015) 2167–2174 2171
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Fig. 4. Phenotypic analysis of Gag-speciﬁc memory T cells. Gag-speciﬁc responses were
analyzed by ﬂow cytometry using an antibody cocktail for memory markers. (A) Dot
plot overlays show the phenotypic characterization (CM-like: CD95+CD28+; effector
memory EM:  CD95+CD28−) of the Gag-speciﬁc T cells induced by rubella vector
type 3 vaccination in macaque DCVV at the day of vaccination and 2 weeks later.
(B)  The percentage of Gag-speciﬁc IFN-+ T cells with CM-like and EM cells are
(
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hat a prime boost vaccine regimen combining rubella vectors and
NA vaccine greatly enhances the T cell responses to antigens such
s SIV Gag.
.6. Durability
We  also monitored the durability of cellular immunity induced
y the rubella vector. All macaques showed persistence of the Gag
 cell responses monitored for ∼4–14 months after the last rubella
oost (Fig. 3A–C). Fig. 3A shows responses detectable for at least
.5 months after the last rubella vector vaccination (∼0.2% of Gag-
peciﬁc IFN-+ T cells at week 114 of study; upper panel; ∼0.3% of
M9+ CD8+ T cells; lower panel). Fig. 3B shows responses detectable
t 8–11 months after the rubella vector boost (∼0.04% to 0.2% of
ag-speciﬁc IFN-+ T cells at week 57 of study; upper panel; ∼0.6%
o 1.1% of CM9+ CD8+ T cells; lower panel). Similarly, Gag T cell
esponses were found even 11 months after a single rubella vector
accination, albeit at low levels (Fig. 3C). Both Gag-speciﬁc IFN-+
 cell responses and tetramer responses showed persistence after
he 2nd rubella vector vaccination. Two of the animals (J6L, V584)
ere examined at 14 months after the 2nd rubella vector boost
nd maintained ∼0.5% of CM9+ T cells (Fig. 3B). Thus, rubella vector
oost was potent in inducing durable responses.
.7. Characterization of the rubella vector vaccine induced
ag-speciﬁc T cell responses
Fig. 4A shows the memory phenotype, central memory-like
CM, CD95+CD28+) and effector memory (EM, CD95+CD28−) in
BMC from a representative animal (macaque DCVV) with the
ag-speciﬁc T cells induced upon vaccination with rubella vector
verlaid in red. The memory T cell subsets were analyzed upon
riming with either rubella vector or DNA (Fig. 4B). Macaques CL6A,
L6J and DCVV showed induction of CM-like and EM T cells produc-
ng IFN-, with more cells having a CM-like phenotype. Subsequent
accinations with rubella vector (CL6A and CL6J), DNA only (CL67),
r DNA followed by rubella vector (CCL49, and DCVV) showed a
imilar distribution of antigen-speciﬁc EM and CM T cells, except
L6A which preferentially accumulated Gag-speciﬁc effector cells
pon boosting with the rubella vector. Similarly, we found that DNA
riming vaccination (CL67, CL49, J6L, V584, V200) induced both
M-like and EM Gag-speciﬁc T cells, with a greater proportion of
M-like T cells. Subsequent vaccinations with rubella vectors (J6L,
584, V200) did not change the distribution of the antigen-speciﬁc
emory T cells. Together, these data show that rubella vector vac-
ination was able to potently prime and boost Gag-speciﬁc T cells
aving CM-like and EM phenotypes.
Analysis of the cytotoxic potential of the Gag-speciﬁc T cells
Fig. 5) after priming with rubella vector (CL6A, CL6J, CL49, CL67,
CVV) or with gag DNA (J6L, V854, V200) was performed 2 weeks
ost-immunization. After a single vaccination with rubella vector,
hree of the ﬁve macaques (CL6A, CL6J, DCVV) showed a subset
f IFN-+ and GzmB+ double-positive T cells, demonstrating the
resence of cytotoxic Gag-speciﬁc T cells. This T cell subset was
lso found upon boosting with either rubella vector (CL6A, CL6J)
r with gag DNA followed by rubella vector (CL49, CL67, DCVV). As
reviously reported [33,34,40,43], priming with DNA induced Gag-
peciﬁc T cells with cytotoxic potential (macaques J6L, V584, V200).
onitoring the cellular responses upon subsequent heterologous
B) (J6L, V584, V200, CL6V (weeks 57–59) and (C) (CL6A, CL6J; weeks 100–102). Right pan
584,  CL6V (weeks 57–59) and (C) (CL6A; weeks 100–102). (E) Changes in cellular immu
FN-+ T cells (left panel) and CM9  tetramer-speciﬁc CD8+ T cells (right panel) responses a
sing  paired t test. Left panel includes data from 6 macaques shown in (A) (CL49, CL67, 
ata  from 4 macaques shown in (A) (CL49; weeks 100–102) and (B) (J6L, V584, at weeks 2shown 2 weeks after the indicated vaccinations. Responses in macaque CL6V could
not be analyzed (see Fig. 3). Neg* indicates absence of detectable Gag-speciﬁc T cell
responses.
boosting with rubella vectors conﬁrmed that the antigen-speciﬁc
cytotoxic T cell subsets were maintained. We  also found the pres-
ence of TNF- producing Gag-speciﬁc T cells and a subset of TNF-+
and GzmB+ double-positive T cells after vaccination with vector
type 3 (CL6A, DCVV) and after vaccination with vector type 3* (CL49,
DCVV, J6L, V585, V200) (data not shown). Taken together, these
data demonstrate that rubella vector vaccination induces strong
Gag-speciﬁc responses with cytotoxic potential (GzmB+).
4. DiscussionWe examined the cellular immune responses induced upon
vaccination with recombinant rubella vectors expressing regions
of SIV Gag and found that these vectors induce robust
el includes data from 5 macaques depicted in (A) (CL49; weeks 100–102), (B) (J6L,
nity in DNA-primed macaques upon rubella vector boost comparing Gag-speciﬁc
t day of vaccination and 2 weeks after rubella vector boost. P values were obtained
DCVV; weeks 100–102) and (B) (J6L, V584, V200 (weeks 27). Right panel includes
5–27, and CL6V at weeks 100–102).
2172 M. Rosati et al. / Vaccine 33
Fig. 5. Analysis of the cytotoxic potential of the Gag-speciﬁc T cells. Gag-speciﬁc T
cells were analyzed by ﬂow cytometry for production of IFN- and the presence of
granzyme B+ (GzmB) 2 weeks after the indicated vaccinations. The responses were
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ositive antigen-speciﬁc T cells and IFN-+ GzmB− single positive cells are shown.
eg* indicates absence of detectable Gag-speciﬁc responses, as in Fig. 4.
ntigen-speciﬁc responses (up to ∼0.2% Gag-speciﬁc IFN-+ T
ells; ∼3% CM9+ CD8+ T cells). This vaccine modality was able to
nduce Gag-speciﬁc responses of a magnitude comparable to those
btained upon a single gag DNA vaccination using the efﬁcient EP
elivery method. Such levels are higher than those found using
ther viral vectors such as MVA, Adenovirus or VSV and which were
ound to greatly beneﬁt from a DNA prime [5,6,11,15–17,22–25].
he rubella vector induced a balanced Gag-speciﬁc T cells immune
esponses mediated by CD4+ and CD8+ T cells with effector and
entral memory-like phenotype. In addition, the antigen-speciﬁc
FN-+ T cells harbor granzyme B, indicating cytotoxic potential.
Sequential vaccination showed that the rubella vector could
lso signiﬁcantly boost preexisting responses, often reaching peak
evels even higher than those induced by DNA vaccine alone.
emarkably, although the rubella vector boosts were given after
rolonged rest periods (∼12–18 months), the responses rapidly
ncreased, supporting their potency. In spite of the presence of
nti-rubella antibodies, a 2nd dose of rubella vectors was able
o signiﬁcantly boost T cell responses, regardless of the order of
he primary immunization with rubella vector and DNA vaccines
Fig. 3). Similarly, prior exposure to the rubella vaccine strain
A27/3 did not prevent induction by the rubella vector boost of
ag-speciﬁc antibodies, as reported previously [19], or Gag-speciﬁc
 cell responses reaching up to 3% CM9+ CD8+ T cells (CL6A, Fig. 2).
his is in overall agreement with another report [30], which showed
hat rubella vaccine could boost pre-existing rubella immunity
n previously immunized humans. Thus, priming and boosting of
aïve subjects with rubella vectors containing vaccine inserts is
 feasible application. Our data also show that once the vector has
uccessfully primed a response, it can be used to boost the response,
espite the presence of anti-Rubella antibodies.
Longevity of responses is another critical feature of any vaccine.
he RV144 vaccine trial elicited immunity that waned over time,
nd the transient nature of the vaccine-induced immune responses
s thought to be, at least partially, responsible for the limited vac-
ine efﬁcacy [44]. Although we detected cellular responses induced
y rubella vector alone after ∼1 year in some animals (Fig. 3C), the
esponses had waned considerably. Thus, these responses did not (2015) 2167–2174
show the robustness reported using a recombinant CMV vector [45]
or SIV DNA vaccine [33,34,43,46]. On the other hand, it has been
a common ﬁnding that DNA delivered by different methods has
the remarkable ability to induce persistent immune responses in
non-human primates [34,35,46]. As observed for other viral vec-
tor vaccines (MVA, VSV, vaccinia, adenovirus), the combination of
rubella vectors with DNA prime augmented Gag immunogencity.
Future studies will test the efﬁcacy of recombinant rubella vector
alone or in combination with DNA, two vaccine platforms that are
safe in humans.
The current rubella vectors can accommodate vaccine inserts
up to ∼300 amino acids in length. Thus, rubella vectors could be
used to express well-deﬁned T cell epitopes, or chimeric molecules
expressing a selection of the most conserved epitopes from dif-
ferent HIV clades ([47,48] and references therein). Inclusion of
HIV Gag conserved elements in DNA-based immunogens provided
a critical step to focus the immune responses to such epitopes
by avoiding decoy epitopes, and provided an effective strategy to
broaden responses in vaccinated macaques, while others showed
that responses to a few epitopes led to effective control of viremia
[49]. Alternatively, since Gag-speciﬁc T cells have been associ-
ated with control of viremia in HIV-1 infected people [36–39],
recombinant rubella vectors may  provide an additional method
to induce such responses. Recombinant rubella vectors expressing
Gag display key features of an effective vaccine such as the induc-
tion of robust T cell responses with effector memory and central
memory-like phenotype and cytotoxic potential (this work), and
the stimulation of humoral responses [19]. Additional studies are
needed to assess the efﬁcacy of the recombinant Rubella vector
vaccines as preventive and therapeutic vaccines.
Live-attenuated rubella vaccine has a number of advantages as
a vaccine platform for SIV and HIV: the vector’s safety and potency
have been established in millions of children, and the recombinant
rubella vector presents the immunogen in the context of an ongoing
infection. The immune response to the Gag insert in rubella vectors
includes long-lasting cytotoxic T cells (this report) and antibody
immunity [19]. A strong T cell response may  target infected cells
early, reducing peak viremia, and during the chronic phase of infec-
tion, resulting in lower viral set point. The overlapping host range
(macaque, man) will allow us to test the protective efﬁcacy of new
rubella vectors in the macaque model.
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